Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - Preclinical studies

Neuroscience and Biobehavioral Reviews

Volumn 21, Issue 4, 1997, Pages 455-468

  Danysz, W ^a   Parsons, C G ^a   Kornhuber, J ^b   Schmidt, W J ^c   Quack, G ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Amantadine; Animal models; Brain levels; Mechanism of action; Memantine; Neuroprotection; NMDA receptors; Parkinson's disease; Review; Serum levels

Indexed keywords

AMANTADINE; AMANTADINE DERIVATIVE; ANTIPARKINSON AGENT; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINE UPTAKE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG POTENCY; LOCOMOTION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM;

AMANTADINE; ANIMALS; ANTIPARKINSON AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; MEMANTINE; PARKINSON DISEASE, SECONDARY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0030990693     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(96)00037-1     Document Type: Article

References (151)

1. 1. Allman, S. A.; Campbell, W.; Needham, P. L., Evidence that D145 is limbic specific. British Journal of Pharmacology, 75, 103 1982.
2. 2. Aoki, F. Y.; Sitar, D. S., Clinical pharmacokinetics of amantadine hydrochloride. Clinical Pharmacokinetics, 14, 35-51 1988.
3. 3. Aoki, F. Y.; Sitar, D. S.; Ogilvie, R. I., Amantadine kinetics in healthy young subjects after long-term dosing. Clinical Pharmacokinetics and Therapeutics, 26, 729-736 1979.
4. 4. Apland, J. P.; Cann, F. J., Anticonvulsant effects of memantine and MK-801 in guinea pig hippocampal slices. Brain Research Bulletin, 37, 311-316 1995.
5. 5. Aronstam, R. S.; Eldefrawi, A. T.; Eldefrawi, M. E., Similarities in the binding sites of the muscarinic receptor and the ionic channel of the nicotinic receptor. Biochemical Pharmacology, 29, 1311-1314 1980.
6. 6. Ashroft, F. M.; Kerr, A. J.; Gibson, J. S.; Williams, B. A., Amantadine and sparteine inhibit ATP-regulated K-currents in the insulin-secreting beta-cell line. British Journal of Pharmacology, 104, 574-584 1991.
7. 7. Bailey, E. V.; Stone, T. W., The mechanism of amantadine in Parkinsonism: a review. Archives of International Pharmacodynamics, 216, 246-262 1975.
8. 8. Birkmayer, W.; Hornykiewicz, O., Der 3,4-dioxyphenylalanin (= L-dopa)-Effekt bei der Parkinson akinesie. Wien Klinik Wochenschrift, 73, 787-788 1961.
9. 9. Bleidner, W. E.; Harmon, J. B.; Hewes, W. E.; Lynes, T. E.; Hermann, E. C., Absorption, distribution and excretion of amantadine hydrochloride. Journal of Pharmacology and Experimental Therapeutics, 150, 484-490 1965.
10. 10. Bormann, J., Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. European Journal of Pharmacology, 166, 591-592 1989.
11. 11. Brenner, M.; Haass, A.; Jacobi, P.; Schimrigk, K., Amantadine sulphate in treating Parkinson's disease: Clinical effects, psychometric tests and serum concentrations. Journal of Neurology, 236, 153-156 1989.
12. 12. Bresink, I.; Danysz, W.; Parsons, C. G.; Mutschler, E., Different binding affinities of NMDA receptor channel blockers in various brain regions - indication of NMDA receptor heterogeneity. Neuropharmacology, 34, 533-540 1995.
13. 13. Brown, F.; Redfern, P. H., Studies on the mechanism of action of amantadine. British Journal of Pharmacology, 58, 561-567 1976.
14. 14. Bubser, M.; Keseberg, U.; Notz, P. K.; Schmidt, W. J., Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats. European Journal of Pharmacology, 229, 75-82 1992.
15. 15. Burnashev, N.; Schoepfer, R.; Monyer, H.; Ruppersberg, J. P.; Gunther, W.; Seeburg, P. H.; Sakmann, B., Control by asparagine residues of calcium permeability and magnesium blockade in the NMDA receptor. Science, 257, 1415-1419 1992.
16. 16. Carlsson, M.; Carlsson, A., Interaction between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends in Neuroscience, 13, 272-276 1990.
17. 17. Carlsson, M.; Carlsson, A., The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. Journal of Neural Transmission, 75, 221-226 1989.
18. 3H]AMPA binding in rat striatum. Neuroscience Letters, 132, 55-58 1991.
19. 19. Chen, H. S. V.; Pellegrini, J. W.; Aggarwal, S. K.; Lei, S. Z.; Warach, S.; Jensen, F. E.; Lipton, S. A., Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine - therapeutic advantage against NMDA receptor-mediated neurotoxicity. Journal of Neuroscience, 12, 4427-4436 1992.
20. 20. Clements, J. D.; Lester, R. A. J.; Tong, G.; Jahr, C. E.; Westbrook, G. L., The time course of glutamate in the synaptic cleft. Science, 258, 1498-1501 1992.
21. 21. Costall, B.; Naylor, R. J., Neuropharmacological studies on D145 (1,3-dimethyl-5-aminoadamatan). Psychopharmacology, 43, 53-61 1975.
22. 22. Costall, B.; Naylor, R. J.; Pycock, C., The 6-hydroxydopamine rotational model for the detection of dopamine agonist activity: reliability of effect from different locations of 6-hydroxydopamine. Journal of Pharmacy and Pharmacology, 279, 943-946 1975.
23. 23. Danysz, W.; Essmann, U.; Bresink, I.; Wilke, R., Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacology and Biochemistry of Behavior, 48, 111-118 1994.
24. 24. Danysz, W.; Gossel, M.; Zajaczkowski, W.; Dill, D.; Quack, G., Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. Journal of Neural Transmission [Parkinson's Disease Section], 7, 155-166 1994.
25. 25. Danysz, W.; Parsons, C. G.; Bresink, I.; Quack, G., Glutamate in CNS disorders - a revived target for drug development. Drugs News Perspectives, 8, 261-277 1995.
26. 26. Di Chiara, G.; Morelli, M.; Consolo, S., Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends in Neuroscience, 17, 228-233 1994.
27. 27. Dimpfel, W., Effects of memantine on synaptic transmission in the hippocampus in vitro. Arzneimittelforschung, 45-1, 1-5 1995.
28. 28. Dimpfel, W.; Spüler, M., Dizocilpine (MK-801), ketamine and phencyclidine: low doses affect brain field potentials in the freely moving rats in the same way as activation of dopaminergic transmission. Psychopharmacology, 101, 317-323 1990.
29. 29. Dimpfel, W.; Spüler, M.; Koch, R.; Schatton, W., Radioelectroencephalographic comparison of memantine with receptor-specific drugs acting on dopaminergic transmission in freely moving rats. Neuropsychobiology, 18, 212-218 1987.
30. 30. Dunn, J. P.; Henkel, J. G.; Gianutsos, G., Pharmacological activity of amantadine: Effect of N-alkyl substitution. Journal of Pharmacy and Pharmacology, 38, 353-356 1986.
31. 31. Edby, K.; Larsson, J.; Eek, M.; von Wendt, L.; Östergard, B., Amantadine treatment of patient with anoxic brain injury. Child's Nervous Systems, 11, 607-609 1995.
32. 32. Ehringer, H.; Hornykiewicz, O., Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klinik Wochenschrift, 38, 1236-1239 1960.
33. 33. Engelsen, B., Neurotransmitter glutamate: its clinical importance. Acta Neurologica Scandinavica, 74, 337-355 1986.
34. 34. Erdo, S. J.; Schafer, M., Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate. European Journal of Pharmacology, 198, 215-217 1991.
35. 35. Farnebo, L.-O.; Fuxe, K.; Goldstein, M.; Hamberger, B.; Ungerstedt, U., Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease. European Journal of Pharmacology, 16, 27-38 1971.
36. 36. Feiling, C., The effect of adding amantaddine to optimum L-DOPA dosage in Parkinson's syndrome. Acta Neurologica Scandinavica, 49, 245-251 1973.
37. 37. Frankiewicz, T.; Potier, B.; Bashir, Z. I.; Collingridge, G. L.; Parsons, C. G., Comparison of the effects of memantine and MK-801 on NMDA-induced current responses in cultured neurones and on synaptic transmission and LTP in area CA1 of the rat hippocampus in vitro. British Journal of Pharmacology, 117, 689-697 1996.
38. 38. Globus, M. Y. T.; Busto, R.; Martinez, E.; Valdes, I.; Dietrich, W. D.; Ginsberg, M. D., Comparative effect of transient global ischemia on extracellular levels of glutamate, glycine, and gamma-aminobutyric acid in vulnerable and nonvulnerable brain regions in the rat. Journal of Neurochemistry, 57, 470-478 1991.
39. 39. Goodwin, P. ; Starr, B. S.; Starr, M. S., Motor responses do dopamine-D1 and dopamine-D2 agonists in the reserpine-treated mouse are affected differentially by the NMDA receptor antagonist MK-801. Journal of Neural Transmission [Parkinson's Disease Section], 4, 15-26 1992.
40. 40. Greenamyre, J. T.; O'Brien, C. F., N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Archives in Neurology, 48, 977-981 1991.
41. 41. Grossmann, A.; Grossmann, W.; Jurna, I., The effect of dimethylaminoadamantane on neuronal membranes. European Journal of Pharmacology, 35, 379-388 1976.
42. 42. Gualtieri, T.; Chandler, M.; Coons, T. B.; Brown, L. T., Amantadine: a new clinical profile for traumatic brain injury. Clinical Neuropharmacology, 12, 258-270 1989.
43. 43. Hauber, W.; Schmidt, W. J., The NMDA antagonist dizocipline (MK-801) reverses haloperidol-induced movement initiation deficits. Behavioral Brain Research, 41, 161-166 1990.
44. 3H]dopamine in rat brain slices. European Journal of Pharmacology, 20, 156-160 1972.
45. 45. Henkel, J. G.; Hane, J. T.; Gianutsos, G., Structure antiParkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution. Journal of Medical Chemistry, 25, 51-56 1982.
46. 46. Honegger, U. E.; Quack, G.; Wiesmann, U. N., Evidence for lysosomotropism of memantine in cultured human cells - cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission. Pharmacology and Toxicology, 73, 202-208 1993.
47. 47. Jackisch, R.; Link, T.; Neufang, B.; Koch, R., Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine - no evidence for direct dopaminomimetic or antimuscarinic properties. Archives of International Pharmacodynamics and Therapeutics, 320, 21-42 1992.
48. 48. Janiec, W.; Piekarska, T.; Paletko, Z.; Pytlik, M., The effect of drugs stimulating central dopaminergic system on transformation of exogenous adenine into c-AMP. Polish Journal of Pharmacology and Pharmacy, 30, 529-535 1978.
49. 49. Janiec, W.; Piekarska, T.; Szczypior, M.; Misterkiewicz, E., The effect of apomorphine, amantadine and dimethylaminoadamantane on the level of cyclic AMP in the rat striatum. Polish Journal of Pharmacology and Pharmacy, 29, 93-99 1977.
50. 50. Jiang, Z. G.; North, R. A., Membrane properties and synaptic responses of rat striatal neurones in vitro. Journal of Physiology (London), 443, 533-553 1991.
51. 51. Jorgensen, H. A.; Andreassen, O. A., Memantine inhibits the development of haloperidol-induced persistent oral movements in rats. Society of Neuroscience Abstracts, 21, 470 1995.
52. 52. Karobath, M. E., Amantadine and D-145, an amantadine derivative, do not effect dopamine sensitive adenyllate cyclase from the caudate-putamen of the rat brain. European Journal of Pharmacology, 28, 376-378 1974.
53. 53. Kawajiri, S.; Dingledine, R., Multiple structural determinants of voltage-dependent magnesium block in recombinant NMDA receptors. Neuropharmacology, 32, 1203-1211 1993.
54. 54. Keilhoff, G.; Wolf, G., Memantine prevents quinolinic acid-induced hippocampal damage. European Journal of Pharmacology, 219, 451-454 1992.
55. 55. Klee, M. R., The effect of memantine on membrane properties and postsynaptic potentials in neurons of Aplysia californica. Arzneimittelforschung, 32, 1259-1267 1982.
56. 56. Klockgether, T.; Turski, L., NMDA antagonists potentiate antiparkinsonian action of L-DOPA in monoamine-depleted rats. Annals of Neurology, 28, 539-546 1990.
57. 57. Klockgether, T.; Turski, L., Toward an understanding of the role of glutamate in experimental parkinsonism - agonist-sensitive sites in the basal ganglia. Annals of Neurology, 34, 585-593 1993.
58. 58. Kornhuber, J.; Bormann, J.; Hubers, M.; Rusche, K.; Riederer, P., Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel - a human postmortem brain study. European Journal of Pharmacology, 206, 297-300 1991.
59. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. European Journal of Pharmacology, 166, 589-590 1989.
60. 60. Kornhuber, J.; Quack, G., Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neuroscience Letters, 195, 137-139 1995.
61. 61. Kornhuber, J.; Quack, G.; Danysz, W.; Jellinger, K.; Danielczyk, W.; Gsell, W.; Riederer, P., Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology, 34, 713-721 1995.
62. 62. Kornhuber, J.; Retz, W.; Riederer, P., Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? Journal of Neural Transmission, 46 (Suppl.), 311-319 1995.
63. 63. Kornhuber, J.; Schoppmeyer, K.; Riederer, P., Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex. Neuroscience Letters, 163, 129-131 1993.
64. 64. Kornhuber, J.; Weller, M.; Schoppmeyer, K.; Riederer, P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. Journal of Neural Transmission 91-104; 1994.
65. 65. Lampe, H.; Bigalke, H., Modulation of glycine activated membrane current by adamantane derivatives. Neuro Report, 2, 373-376 1991.
66. 66. Lassen, J., The effect of amantadine and (+)-amphetamine on motylity in rats after inhibition of monoamine synthesis and storage. Psychopharmacologia, 29, 55-64 1973.
67. 67. Löscher, W.; Annies, R.; Honack, D., Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats. European Journal of Pharmacology, 242, 263-274 1993.
68. 68. Lupp, A.; Lucking, C. H.; Koch, R.; Jackisch, R.; Feuerstein, T. J., Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. Journal of Pharmacology and Experimental Therapeutics, 263, 717-724 1992.
69. 69. Lustig, H. S.; Ahern, K. V.; Greenberg, D. A., Antiparkinsonian drugs and invitro excitotoxicity. Brain Research, 597, 148-150 1992.
70. 70. Maj, J., Effect of memantine on central neurotransmitter systems. Review of the results. Arzneimittelforschung, 32, 1256-1259 1982.
71. 71. Maj, J.; Sowinska, H.; Baran, L., The effect of amantadine on motor activity and catalepsy in rats. Psychopharmacology, 24, 296-307 1972.
72. 72. Maj, J.; Sowinska, H.; Baran, L.; Sarnek, J., Pharmacological effects of 1,3-dimethyl-5-aminoadamantane, a new adamantane derivative. European Journal of Pharmacology, 26, 9-14 1974.
73. 73. Masuo, K.; Enomoto, K.; Maeno, T., Effects of memantine on the frog neuromuscular junction. European Journal of Pharmacology, 130, 187-195 1986.
74. 74. Matsubayashi, H.; Albuquerque, E. X., Inhibitory effects of the antiviral agent amantadine on nicotinic acetylcholine responses in rat hippocampal cultured neurons. Society of Neuroscience Abstracts, 21, 18-34 1995.
75. 75. Meldrum, B., Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters. Clinical Science, 68, 113-122 1985.
76. 76. Menon, M. K.; Clark, W. G., GABA-ergic drugs block the locomotor stimulant effects of 1,3-dimethyl-5-aminoadamantane (D-145). Neuropharmacology, 18, 223-225 1979.
77. 77. Menon, M. K.; Clark, W. G., Pharmacological evidence for the involvement of GABA-ergic system in the locomotor stimulation produced in mice by 1,3-dimethyl-5-aminoadamantane (D-145). Neuropharmacology, 17, 1049-1052 1978.
78. 78. Menon, M. K.; Vivonia, C. A.; Haddox, V. G., Evidence for presynaptic antagonism by amantadine of indirectly acting central stimulants. Psychopharmacology, 82, 89-92 1984.
79. 79. Messiha, F. S., Effect of amantadine on chlorpromazine and reserpine-induced behavioral depression in the mouse. Neuroscience and Biobehavioral Reviews, 12, 219-222 1988.
80. 80. Mistry, R.; Wilke, R.; Challiss, R. A. J., Modulation of NMDA effects on agonist-stimulated phosphoinositide turnover by memantine in neonatal rat cerebral cortex. British Journal of Pharmacology, 114, 797-804 1995.
81. 81. Misztal, M.; Frankiewicz, T.; Parsons, C. G.; Danysz, W., Learning deficit induced by chronic intraventricullar infusion of quinolinic acid - protection by MK-801 and memantine. European Journal of Pharmacology, 296, 1-8 1996.
82. 82. Mizoguchi, K.; Yokoo, H.; Yoshida, M.; Tanaka, T.; Tanaka, M., Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism. Brain Research, 662, 255-258 1994.
83. 83. Mizuno, Y.; Mori, H.; Kondo, T., Potential of neuroprotective therapy in Parkinsons disease. CNS Drugs, 1, 45-56 1994.
84. 84. Monyer, H.; Sprengel, R.; Schoepfer, R.; Herb, A.; Higuchi, M.; Lomeli, H.; Burnashev, N.; Sakmann, B.; Seeburg, P. H., Heteromeric NMDA receptors - molecular and functional distinction of subtypes. Science, 256, 1217-1221 1992.
85. 85. Morelli, M.; Fenu, S.; Pinna, A.; Dichiara, G., Opposite effects of NMDA receptor blockade on dopaminergic D1-mediated and D2-mediated behavior in the 6-hydroxydopamine model of turning -relationship with c-fos expression. Journal of Pharmacoly and Experimental Therapeutics, 260, 402-408 1992.
86. 86. Moryl, E.; Danysz, W.; Quack, G., Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacology and Toxicology, 72, 394-397 1993.
87. 87. Müller, W. E.; Mutschler, E.; Riederer, P., Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry, 28, 113-124 1995.
88. 88. Nankai, M.; Fage, D.; Carter, C., NMDA receptor subtype selectivity: eliprodil, polyamine spider toxins, dextromethorphan, and desipramine selectively block NMDA-evoked striatal acetylcholine but not spermidine release. Journal of Neurochemistry, 64, 2043-2048 1995.
89. 89. Netzer, R.; Binscheck, T.; Koch, R.; Bigalke, H. Memantine: suppression of high frequency action potentials is caused by prolongation of the refractory period of the sodium current. Berlin, Heidelberg: Springer Verlag; 217-221;1991.
90. 90. Neugebauer, V.; Kornhuber, J.; Lucke, T.; Schaible, H. G., The clinically available NMDA receptor antagonist memantine is antinociceptive on rat spinal neurones. Neuro Report, 4, 1259-1262 1993.
91. 91. Osborne, N. N.; Quack, G., Memantine stimulates inositol phosphates production in neurones and nullifies N-methyl-D-aspartate-induced destruction of retinal neurones. Neurochemistry International, 21, 329-336 1992.
92. 92. Ossowska, K., The role of excitatory amino acids in experimental models of parkinson's disease. Jouranl of Neural Transmission [Parkinson's Disease Section], 8, 39-71 1994.
93. 93. Pacifici, G. M.; Nardini, M.; Ferrari, P.; Latini, R.; Fieschi, C.; Morselli, P. L., Effect of amantadine on drug-induced parkinsonism: relationship between plasma levels and effects. British Journal of Clinical Pharmacology, 3, 883-889 1976.
94. 94. Papeschi, R., Amantadine may stimulate dopamine and noradrenaline receptors. Neuropharmacology, 13, 77-83 1974.
95. 95. Parsons, C. G.; Gruner, R.; Rozental, J.; Millar, J.; Lodge, D., Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology, 32, 1337-1350 1993.
96. 96. Parsons, C. G.; Panchenko, V. A.; Pinchenko, V. O.; Tsyndrenko, A. Y.; Krishtal, O. A., Comparative patch clamp studies with freshly dissociated rat hippocampal and striatal neurones on the NMDA receptor antagonistic effects of amantadine and memantine. European Journal of Neuroscience, 8, 446-454 1996.
97. 97. Parsons, C. G.; Quack, G.; Bresink, I.; Baran, L.; Przegalinski, E.; Kostowski, W.; Krzascik, P.; Hartmann, S.; Danysz, W., Comparison of the potency, kinetics and voltage-dependency of open channel blockade for a series of uncompetitive NMDA antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology, 34, 1239-1258 1995.
98. 98. Porter, R. H. P.; Greenamyre, J. T., Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. Journal of Neurochemistry, 64, 614-623 1995.
99. 99. Prado de Carvalho, L.; Bochet, P.; Rossier, J., NMDA receptors expressed in oocytes: effects of ligands related to HIV infection. Society of Neuroscience Abstracts, 19.16, 730 1993.
100. 100. Quack, G.; Hesselink, M.; Danysz, W.; Spanagel, R., Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. Journal of Neural Transmission, 46 (Suppl.), 95-102 1995.
101. 101. Rabey, J. M.; Nissipeanu, P.; Korczyn, A. D., Efficacy of memantine, and NMDA receptor antagonist, in the treatment of Parkinson's disease. Journal of Neural Transmission [Parkinson's Disease Section], 4, 277-282 1992.
102. 102. Randrup, A.; Mogilnicka, E., Pharmacology of monoaminergic mechanisms. Polish Journal of Pharmacology and Pharmacy, 28, 551-556 1976.
103. 103. Reiser, G.; Binmoller, F.; Koch, R., Memantine (1-amino-3,5-dimethyladamantane) blocks the serotonin-induced depolarization response in a neuronal cell line. Brain Research, 443, 338-344 1988.
104. 2+ activity and of cyclic GMP level in a neuronal cell line. European Journal of Pharmacology [Molecular Pharmacology], 172, 199-203 1989.
105. 105. Rizzo, M.; Biandrate, P.; Tognoni, G.; Morselli, P. L., Amantadine in depression: relationship between behavioural effects and plasma levels. European Journal of Clinical Pharmacology, 5, 226-228 1973.
106. 106. Rohrbacher, J.; Bijak, M.; Misgeld, U., Suppression by memantine and amantadine of synaptic excitation intrastriatally evoked in rat neostriatal slices. Neuroscience Letters, 182, 95-98 1994.
107. 107. Rojas, P.; Altagracia, M.; Kravzov, J.; Rios, C., Amantadine increases striatal dopamine turnover in MPTP-treated mice. Drug Development Research, 29, 222-226 1993.
108. 108. Sanger, D. J.; Terry, P.; Katz, J. L., Memantine has phencyclidine-like but not cocaine-like discriminative stimulus effects in rats. Behavioral Pharmacology, 3, 265-268 1992.
109. 109. Scatton, B.; Cheramy, A.; Besson, M. J.; Glowinski, J., Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. European Journal of Pharmacology, 13, 131-133 1970.
110. 110. Schmidt, W. J., Intrastriatal injection of DL-2-amino-5-phosphono-valeric acid (AP-5) induces sniffing stereotypy that is antagonised by haloperidol and clozapine. Psychopharmacology, 90, 123-130 1986.
111. 111. Schmidt, W. J.; Bubser, M., Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacology and Biochemistry of Behavior, 32, 621-623 1989.
112. 112. Schmidt, W. J.; Bubser, M.; Hauber, W., Behavioural pharmacology of glutamate in the basal ganglia. Journal of Neural Transmission [General Section, Suppl.], 38, 65-89 1992.
113. 113. Schmidt, W. J.; Zadow, B.; Kretschmer, B. D.; Hauber, W., Anticataleptic potencies of glutamate-antagonists. Amino Acids, 1, 225-237 1991.
114. 114. Schneider, E.; Fischer, P. A.; Clemens, R.; Balzereit, F.; Funfgeld, E. W.; Haase, H. J., Effects of oral memantine administration on Parkinson's symptoms. Results of placebo-controlled multicenter study. Deutsch Medizin Wochenschrrift, 109, 987-990 1984.
115. 115. Schwab, R. S.; England, A. C.; Poskranzer, D. C.; Young, R. R., Amantadine in the treatment of Parkinson's disease. Journal of the American Medical Association, 208, 1168-1170 1969.
116. 116. Schwarz, M.; Block, F.; Sontag, K. H., Normal N-methyl-D-aspartate (NMDA)-mediated muscle relaxant action of memantine in rats. Neuroscience Letters, 143, 105-109 1992.
117. 117. Skuza, G.; Rogoz, Z.; Quack, G.; Danysz, W., Memantine, amantadine, and L-deprenyl potentiate the action of L-DOPA in monoamine-depleted rats. Journal of Neural Transmission [General Section], 98, 57-67 1994.
118. 118. Snell, L. D.; Johnson, K. M., Antagonism of N-methyl-D-aspartate-induced transmitter release in the rat striatum by phencyclidine-like drugs and its relationship to turning behavior. Journal of Pharmacology and Experimental Therapeutics, 235, 50-57 1985.
119. 119. Sonsalla, P. K.; Nicklas, W. J.; Heikkila, R. E., Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science, 243, 398-400 1989.
120. 120. Spanagel, R.; Eilbacher, B.; Wilke, R., Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat - a pharmacokinetic microdialysis study. European Journal of Pharmacology, 262, 21-26 1994.
121. 121. Starr, M. S., Glutamate/dopamine d-1/d-2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse, 19, 264-293 1995.
122. 122. Starr, M. S.; Starr, B. S., Locomotor effects of amantadine in the mouse are not those of a typical glutamate antagonist. Journal of Neural Transmission [Parkinson's Disease Section], 9, 31-43 1995.
123. 123. Stieg, P. E.; Sathi, S.; Alvarado, S. P.; Jackson, P. S.; Pelligrini, J. W.; Chen, H. V.; Lipton, S. A.; Jensen, F. E., Post-stroke neuroprotection by memantine mimally affects behavior and does not block LTP. Society of Neuroscience Abstracts, 19, 1502 1993.
124. 124. Stoof, J. C.; Booij, J.; Drukarch, B.; Wolters, E. C., The antiparkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a noncompetitive way. European Journal of Pharmacology, 213, 439-443 1992.
125. 125. Stpierre, J. A.; Bedard, P. J., Intranigral but not intrastriatal microinjection of the NMDA antagonist MK-801 induces contralateral circling in the 6-OHDA rat model. Brain Research, 660, 255-260 1994.
126. 126. Strömberg, U.; Svensson, T. H., Further studies on the mode of action of amantadine. Acta Pharmacologica et Toxicologica, 30, 161-171 1971.
127. 127. Svensson, T. H., Dopamine release and direct dopamine receptor activation in the central nervous system by D-145, an amantadine derivative. European Journal of Pharmacology, 23, 232-238 1973.
128. 128. Svensson, A.; Carlsson, A.; Carlsson, M. L., Differential locomotor interactions between dopamine-d1/d2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice. Journal of Neural Transmission [General Section], 90, 199-217 1992.
129. 129. Tano, T.; Heluy-Dantas, M. C.; Marchiro, M.; Cintra, W. M.; Aracava, Y.; Albuquerque, E. X.; Schrattenholz, A.; Maelicke, A., The novel agonist site on nicotinic receptor (nAchR): activation by pyrazoles, amantadine and polyamines. Society of Neuroscience Abstracts, 19, 1537 1993.
130. 130. Tilley, J. W.; Kramer, M. J. Amantadine derivatives. In: Ellis, G. P.; West, G. B., eds. Progress in medicinal chemistry, vol. 18. Amsterdam: Elsevier; 1981:1-44.
131. 131. Tomitaka, S.; Hashimoto, K.; Narita, N.; Minabe, Y.; Tamura, A., Amantadine induces c-fos in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists. European Journal of Pharmacology, 285, 207-211 1995.
132. 132. Tsai, M. C.; Chen, M. L.; Lo, S. C.; Tsai, G. C., Effects of memantine on the twitch tension of mouse diaphragm. European Journal of Pharmacology, 160, 133-140 1989.
133. 133. Turski, L.; Bressler, K.; Rettig, K. J.; Loschmann, P. A.; Wachtel, H., Protection of substantia nigra from MPP + neurotoxicity by N-methyl-D-aspartate antagonists. Nature, 349, 414-417 1991.
134. 134. Uitti, R. J.; Rajput, A. H.; Ahlskog, J. E.; Offord, K. P.; Schroeder, D. R.; Ho, M. M.; Prasad, M.; Rajput, A.; Basran, P., Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology, 46, 1551-1556 1996.
135. 135. Ulas, J.; Weihmuller, F. B.; Brunner, L. C.; Joyce, J. N.; Marshall, J. F.; Colman, C. W., Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/ Alzheimer's disease patients: an autoradiographic study. Journal of Neuroscience, 14, 6317-6324 1994.
136. 136. Verspohl, E. J.; Koch, R.; Schatton, W., Interaction of memantine with cholecystokinin receptors in mouse brain. Journal of Pharmacy and Pharmacology, 40, 111-115 1988.
137. 137. von Voigtlander, P. F.; Moore, K. E., Involvement of nigro-striatal neurons in the in vivo release of dopamine by amphetamine, amantadine and tyramine. Journal of Pharmacology and Experimental Therapeutics, 184, 542-552 1973.
138. 138. Wachtel, H.; Kunow, M.; Loschmann, P. A., NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia-nigra lesioned rats. Neuroscience Letters, 142, 179-182 1992.
139. 139. Watkins, J. C.; Evans, R. H., Excitatory amino acid transmitters. Annual Review of Pharmacology and Toxicology, 21, 165-204 1981.
140. 140. Weihmuller, F. B.; Ulas, J.; Nguyen, L.; Cotman, C. W.; Marshall, J. F., Elevated NMDA receptors in parkinsonian striatum. Neuro Report, 3, 977-980 1992.
141. 141. Weller, M.; Finielsmarlier, F.; Paul, S. M., NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons - neuroprotective properties of amantadine and memantine. Brain Research, 613, 143-148 1993.
142. 142. Wenk, G. L.; Danysz, W.; Mobley, S. L., Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Research, 655, 7-11 1994.
143. 143. Wenk, G. L.; Danysz, W.; Mobley, S. L., MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. European Journal of Pharmacy, 293, 267-270 1995.
144. 144. Wenk, G. L.; Danysz, W.; Roice, D. D., NMDA receptor antagonist memantine blocks toxicity mediated by mtochondrial failure and cholinesterase inhibitor within the nucleus basalis magnocellularis. Neuro Report, 7, 1453-1456 1996.
145. 145. Wesemann, W. Therapy of Morbus Parkinson and radical induced neurotoxicity in the rat. In vivo voltammetric studies. Journal of Neural Transmission [Parkinson's Disease Section], 45-53, 1992.
146. 146. Wesemann, W.; Dette-Wildenhahn, G.; Fellehner, H., In vitro studies on the possible effects of 1-aminoadamantanes on the serotonergic system in M Parkinson. Journal of Neural Transmission [General Section], 44, 263-285 1979.
147. 147. Wesemann, W.; Ekenna, O., Effect of 1-aminoadamantanes on the MAO activity in brain, liver, and kidney of the rat. Arzneimittelforschung, 32, 1241-1243 1982.
148. 148. Wesemann, W.; Schollmeyer, J. D.; Sturm, G., Distribution of memantine in brain, liver, and blood of the rat. Arzneimittelforschung, 32, 1243-1245 1982.
149. 149. Wesemann, W.; Sontag, K. H.; Maj, J., On the pharmacodynamics and pharmacokinetics of memantine. Arzneimittelforschung, 33, 1122-1134 1983.
150. 150. Wesemann, W.; Sturm, G.; Fünfgeld, E. W., Distribution and metabolism of the potential anti-parkinson drug memantine in the human. Journal of Neural Transmission, 16 (Suppl) 1980.
151. 151. Zetler, G. Anticataleptic actions of amantadine hydrochloride. Archiv fur Experimentalle Pathologie und Phamakologie 266: 1970; 276-278.